This application represents a revised resubmission application for a Specialized Program of Research Excellence (SPORE) in Prostate Cancer from the Prostate Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Prostate Cancer SPORE has been funded for two cycles since 2002. DF/HCC is comprised of the following institutions: Dana-Farber Cancer Institute;Harvard Medical School;Harvard School of Public Health;Beth Israel-Deaconess Medical Center;Brigham and Women's Hospital;Massachusetts General Hospital;and Children's Hospital of Boston. In addition to the institutions in the DF/HCC, the Broad Institute and Massachusetts Institute of Technology are collaborating institutions in this grant. The DF/HCC Prostate Cancer SPORE has its administrative base at the DFCI. Dr. Philip Kantoff, who has led the DF/HCC Prostate Cancer Program and SPORE since their inception, is joined by Co-Directors Dr. William Hahn, a laboratory scientist at DFCI, and Dr. Steven Balk, a laboratory scientist at BIDMC. Dr. Kantoff reports directly to Dr. Edward Benz, Director of DF/HCC and President of DFCI. The DF/HCC Prostate Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 4 Projects which address critical problems in prostate cancer and have translational components including 1) understanding the mechanism by which obesity impacts prostate cancer mortality 2) dissecting the clinical heterogeneity of Gleason 7 prostate cancer 3) understanding the role that genomic change has on resistance to primary androgen deprivation therapy and on aggressive prostate cancer and finally 4) understanding the androgen receptor based mechanisms of resistance in castration resistant disease. The four projects are supported by three Cores - an Administrative Core, a Biostatistics and Computational Biology Core, and a Tissue and Pathology Core. We also have a highly successful Career Development Program that selects talented physician scientists and mentors them to independence as well as a Developmental Projects Program that generates new ideas for the SPORE in the future.

Public Health Relevance

This SPORE is focused on several important themes in prostate cancer: 1) the identification of lethal prostate cancer using genetic and genomic approaches and 2) understanding the role of metabolism on the development of lethal prostate cancer, and understanding the mechanism of primary and secondary resistance to hormonal therapy and finally elucidating new targets for therapy in men with advanced disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090381-11A1
Application #
8548582
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
2001-04-01
Project End
2018-06-30
Budget Start
2013-09-23
Budget End
2014-06-30
Support Year
11
Fiscal Year
2013
Total Cost
$2,150,500
Indirect Cost
$780,326
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Chen, Eddy J; Sowalsky, Adam G; Gao, Shuai et al. (2015) Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res 21:1273-80
Labbé, D P; Zadra, G; Ebot, E M et al. (2015) Role of diet in prostate cancer: the epigenetic link. Oncogene 34:4683-91
Sowalsky, Adam G; Xia, Zheng; Wang, Liguo et al. (2015) Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res 13:98-106
Penney, Kathryn L; Sinnott, Jennifer A; Tyekucheva, Svitlana et al. (2015) Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev 24:255-60
Yu, Ziyang; Chen, Sen; Sowalsky, Adam G et al. (2014) Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 20:1590-600
Crowe, Francesca L; Appleby, Paul N; Travis, Ruth C et al. (2014) Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. J Natl Cancer Inst 106:
Cato, Laura; Neeb, Antje; Brown, Myles et al. (2014) Control of steroid receptor dynamics and function by genomic actions of the cochaperones p23 and Bag-1L. Nucl Recept Signal 12:e005
Sun, T; Wang, X; He, H H et al. (2014) MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 33:2790-800
Priolo, Carmen; Pyne, Saumyadipta; Rose, Joshua et al. (2014) AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res 74:7198-204
Kissick, Haydn T; Sanda, Martin G; Dunn, Laura K et al. (2014) Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One 9:e93231

Showing the most recent 10 out of 149 publications